Most Recent Flipbooks
WCG SiteView Report: Concurrent Open Studies at Site
This is an example WCG report on Concurrent Open Studies at a Site. Click here to request a customized report for your study sites: https://www.wcgclinical.com/about/knowledgebase/siteview/
Study Fast Start Case Study: Small Biopharma
WCG worked with a Small Biopharma company to develop a new model for selecting, initiating and deploying site based enrollment resources in a hyper competitive study landscape.
ACI Clinical Services Overview
We focus on driving best practices in managing Independent Expert Committees by combining our internal expertise and strong academic relationships to deliver a fully integrated approach.
Creating Value for Pfizer
Using PANSS Score Profiles to Predict Early Termination in a Study on Acute Exacerbation of Schizophrenia
Blinded analyses were aimed to determine how different atypical Positive and Negative Syndrome Scale (PANSS) score profiles (identified using algorithms) were able to predict early termination.
Using scoring algorithms to identify serious scoring violations among placebo responders and non-responders in clinical trials using the Pos
The objective was to use a priori scoring algorithm designed to assess violations and non-violations on PANSS items.
Validation of Goal Attainment Scaling for Depression: Initial Findings From an Open-Label Study in Patients Switching to Vortioxetine
Clinical and Amyloid Screen Failure Rates in Episodic Memory Measures of Early AD Trials
Error Rates and Data Integrity: eCOA versus Paper Administration of the PANSS
Independent Telephone-based Assessment of Depressive Symptoms in China
Identifying Elevated Rates of CDR Scoring Errors
The goal of this study was to identify a CDR quality metric, based upon internal patterns of domain scores that could be used to identify atypical patterns that might be indicative of scoring errors.
Increased Signal Detection in Alzheimer's Disease Clinical Trials
This study investigated the impact of lag time on error rates for commonly used Alzheimer’s disease COAs, as well as the degree to which administration attenuated error rates associated with lag time.
RBANS as a Useful Outcome Measure in Prodromal AD Trials